Results 91 to 100 of about 12,163,405 (268)

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso   +5 more
wiley   +1 more source

Conference Report: International Conference on Health Sciences and Medical Technologies, Tlemcen, Algeria 27–29 September 2016 ICHSMT’16

open access: yesElectronic Physician, 2016
The International Conference on Health Sciences and Medical Technologies (ICHSMT’16) was held in Tlemcen, Algeria from 27-29 September 2016. The conference was organized by the University Of Tlemcen, in partnership with Electronic Physician Journal ...
Abdeldjalil Khelassi
doaj   +1 more source

Texas Ethics Commission Rules [PDF]

open access: yes, 2012
Document presenting the 2012 revised edition of Texas Ethics Commission rules listed ...
Texas Ethics Commission
core  

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

open access: yesMolecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau   +9 more
wiley   +1 more source

Ethics Eye නිරීක්ෂකයෙකු වන්න ඔබටත් පුළුවන්!

open access: yes
This entry includes only three infographics (in Sinhala) and no writeups.On January 8, 2024, the Ethics Eye team published a three-slide post on their facebook page encouraging followers and others to join the team as external media ethics violation ...
Ethics Eye
core   +1 more source

Ethics in publishing [PDF]

open access: yesCanadian Urological Association Journal, 2012
openaire   +3 more sources

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

open access: yesMolecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy